Drug Trial Radar · NCT01888497
Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers
Last checked: Nov 20, 2026Latest source record: Feb 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Jul 29, 2013
Primary completion
Dec 14, 2013
Study completion Dec 14, 2013
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will examine the next-day residual effects of a nighttime dose of gabapentin 250 mg, diphenhydramine citrate 76 mg and triazolam 0.5 mg compared to placebo and each other on simulated driving performance in normal volunteer subjects. It will also examine other measures of next-day performance and next-day sleepiness.
Conditions
- Healthy
Interventions
GabapentinDrug
250 mg, oral, prior to bedtime on the night before performance testing
Diphenhydramine citrateDrug
76 mg, oral, prior to bedtime on the night before performance testing
TriazolamDrug
0.5 mg, oral, prior to bedtime on the night before performance testing
PlaceboDrug
Oral, prior to bedtime on the night before performance testing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Standard Deviation of Lateral Position (SDLP)Time frame: 7.25 hours post-dose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Baptist Sleep Centers, LLP
South Miami, Florida
Miami Research Associates
South Miami, Florida
NeuroTrials Research Sleep Lab
Atlanta, Georgia
NeuroTrials Research, Inc.
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.